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Abbreviations 
 
AFS: amniotic fluid stem cells 
BM: bone marrow 
Ctx: cardiotoxin 
EDL: extensor digitorum longus 
ES: embryonic stem cells 
FL: fetal liver 
GFP: green fluorescent protein 
PCR: polymerase chain reaction 
pt: post transplantation 
SC: satellite cells 
SMA: spinal muscular atrophy 
SMN: survival motor neuron gene 
TA: tibialis anterior  
WT: wild type 
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i. Riassunto 
 
Introduzione: Negli ultimi anni lo studio delle cellule staminali ha suscitato molto 
interesse, sia per il grande potenziale di queste cellule nelle terapie e applicazioni 
cliniche, sia come modello di studio in vitro per diversi tipi di malattie. In 
particolare, le cellule staminali embrionali hanno una elevata capacità 
proliferativa e di differenziazione, ma il loro utilizzo è ancora associato a 
problematiche etiche. Anche le cellule staminali adulte possiedono grandi 
potenzialità differenziative sia in vitro che in vivo, tuttavia il loro utilizzo è 
limitato in quanto difficili da isolare ed espandere, soprattutto in ambito clinico. 
In questo scenario sarebbe vantaggioso poter ottenere una popolazione di 
cellule con elevata capacità di proliferazione e differenziazione, senza dover 
affrontare però problemi di tipo etico. Nel 2007 il nostro gruppo ha isolato una 
popolazione di cellule staminali dal liquido amniotico (cellule AFS), utilizzando 
come marcatore il recettore c-Kit. Queste cellule hanno capacità clonogenica e 
possono essere dirette a differenziare in una vasta gamma di tipi cellulari 
appartenenti a tutti e tre i foglietti germinativi. 
Obiettivo: Questo lavoro mira a caratterizzare il potenziale miogenico delle 
cellule staminali del liquido amniotico di topo utilizzando un modello murino di 
atrofia spinale muscolare. In particolare è volto ad analizzare la capacità delle 
cellule AFS di dare origine a cellule staminali muscolari e colonizzare la nicchia 
staminale del muscolo scheletrico. 
Materiali e Metodi: Le cellule AFS sono state ottenute mediante amniocentesi e 
selezionate per la positività al marcatore c-kit con metodo immmunomagnetico. 
Appena isolate le cellule AFS sono state analizzate per l'espressione di diversi 
marcatori (CD90, CD45, CD44, CD34, CD31, Flk1, SCA1, CD105) tramite citometria 
a flusso; inoltre, attraverso qRT-PCR è stata analizzata l'espressione di Oct4, 
Sox2, c-Myc, Klf4 e Sca-1 delle cellule AFS isolate a diversi stadi embrionali. 
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Per la terapia di topi transgenici HSA-Cre, Smn
F7/F7
, le cellule AFS GFP+ sono state 
iniettate per via sistemica attraverso la vena caudale; gli animali sono stati poi 
sacrificati a uno e a quindici mesi dopo il trapianto. Sono stati osservati e 
analizzati alcuni parametri clinici per valutare l’effetto del trapianto cellulare. 
Diversi muscoli sono stati raccolti ed analizzati con ematossilina e eosina, 
tricromica di Masson e mediante immunofluorescenza con anticorpi anti-GFP e 
anti-distrofina. Per dimostrare la capacità delle cellule AFS di colonizzare la 
nicchia staminale del muscolo, sono state eseguite delle immunofluorescenze 
per i marcatori specifici delle cellule satelliti e sono stati eseguiti dei trapianti 
secondari. Il potenziale miogenico delle cellule AFS è stato valutato anche con 
trapianto dopo espansione in vitro. 
Risultati: Il numero medio di cellule AFS presenti nel liquido amniotico varia nel 
corso della gestazione murina; all’età di 12.5 giorni queste cellule sono circa l’1% 
del totale ed esprimono marcatori ematopoietici (CD45, CD34, SCA1), marcatori 
mesenchimali (CD90, CD105) unitamente a Flk1, CD31 e CD44. L’analisi di 
espressione genica ha dimostrato che le cellule AFS esprimono a bassi livelli Oct4 
e Sox2 e alti livelli di c-Myc e Klf4, mentre, nonostante la composizione mista di 
questa popolazione, non è stata rilevata espressione di marcatori o fattori di 
trascrizione tipici dei precursori muscolari. 
I topi HSA-Cre, Smn
F7/F7
 mediamente muoiono all'età di 10 mesi e durante il 
corso della loro vita mostrano evidenti complicazioni cliniche come una 
pronunciata cifosi e atrofia a livello muscolare. Dopo il trapianto con cellule AFS 
GFP+ o con cellule del midollo osseo, il tasso di sopravvivenza di questi animali 
aumenta rispettivamente del 75% e 50%. Gli animali trattati con cellule AFS 
hanno recuperato più del 75% della forza rispetto agli animali non trattati. Un 
mese dopo il trapianto, i muscoli di topi trattati con cellule AFS presentano il 37% 
di fibre GFP+, un numero molto basso di miofibre rigeneranti (< 1%) ed una 
normale espressione di distrofina. Quindici mesi dopo il trapianto, gli animali 
trattati con cellule del midollo osseo mostrano un elevato numero di fibre centro 
nucleate, un’importante infiltrazione di tessuto interstiziale e nessuna miofibra 
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GFP+, mentre i topi trattati con cellule AFS hanno un fenotipo molto simile a 
quello di topi sani della stessa età, e il 58% delle miofibre è GFP+. Risultati simili 
sono stati ottenuti trattando lo stesso modello animale con cellule AFS dopo 
espansione in cultura. 
Discussione: Le cellule AFS isolate dal liquido amniotico di topo sono una 
popolazione eterogenea; queste cellule esprimono marcatori mesenchimali, 
ematopoietici e marcatori endoteliali. Va evidenziato che, nonostante la 
composizione mista di questa popolazione staminale, non esistono precursori 
muscolari al suo interno, e quindi qualunque differenziamento in senso 
muscolare di queste cellule è dovuto ad una differenziazione delle cellule AFS e 
non ad una maturazione di cellule già pre-commited.   
Quando vengono iniettate in un modello di atrofia muscolare, le cellule AFS 
mostrano un grande  potenziale miogenico, anche a lungo termine, 
dimostrandosi una interessante fonte cellulare per scopi terapeutici. Queste 
cellule infatti sono state in grado di differenziare in cellule satelliti localizzandosi 
nella nicchia delle cellule staminali muscolari ed esprimendo Pax7, α7integrina e 
SM/c-2.6, tutti marcatori esclusivi delle cellule satelliti. Inoltre, le cellule AFS 
possono contribuire alla formazione di nuove miofibre anche dopo espansione in 
cultura, aumentando così lo spettro di possibili applicazioni terapeutiche. 
 
Parte del materiale prodotto nei tre anni di studio ha portato alla pubblicazione 
di un articolo scientifico:  
Amniotic fluid stem cells restore the muscle cell niche in a HSA-Cre, Smn(F7/F7) 
mouse model. 
Piccoli M, Franzin C, Bertin E, Urbani L, Blaauw B, Repele A, Taschin E, Cenedese 
A, Zanon GF, André-Schmutz I, Rosato A, Melki J, Cavazzana-Calvo M, Pozzobon 
M, De Coppi P. 
Stem Cells. 2012 Aug;30(8):1675-84. doi: 10.1002/stem.1134. 
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ii. Abstract 
 
Introduction: Stem cell biology has received much interest because of its 
potential in both therapeutic application and in vitro modeling of diseases. In 
particular embryonic stem cells have good proliferative and differentiative 
abilities, but their use is still associated to ethical concerns and problems related 
to their teratogenic potential. Adult stem cells have also been described to be 
pluripotent both in vitro and in vivo. However, their use is limited because they 
are difficult to isolate and expand, particularly in a clinical setting. In this 
scenario, it would be advantageous to obtain a cell population with high self-
renewal and differentiation capacities, without ethical problems. In 2007 our 
group described that amniotic fluid stem (AFS) cells could be derived selecting 
amniocytes using c-Kit antibody. AFS cells have clonogenic capability and can be 
directed into a wide range of cell types representing the three primary 
embryonic lineages. 
Aim: This work aiming at characterize the myogenic potential of mouse AFS cells 
using a mouse model of spinal muscular atrophy and in particular at analyzing 
their ability to differentiate into satellite cells and colonize the muscle stem cell 
niche. 
Materials and Methods: Mouse AFS cells were obtained by amniocentesis and 
selected for the marker c-Kit with immunomagnetic beads. Freshly isolated AFS 
cells were analyzed for the expression of different markers (CD90, CD45, CD44, 
CD34, CD31, Flk1, SCA1, CD105) by flow cytometry and the expression of Oct4, 
Sox2, c-Myc, Klf4 and Sca-1 by qRT-PCR at different embryonic stages. 
For the treatment of HSA-Cre, Smn
F7/F7 
mutant mice, GFP+ AFS cells were 
injected via the tail vein and animals were sacrificed one and fifteen months 
after transplantation. Clinical aspects were observed and analyzed after 
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transplantation to evaluate AFS cells’ effects. Several muscles were stained with 
hematoxylin and eosin, Masson’s trichrome and analyzed by 
immunofluorescence with anti-GFP and anti-dystrophin antibodies. To 
demonstrate the ability of AFS cells to replenish the muscle niche, staining for 
satellite cell markers and secondary transplantation were performed. The 
myogenic potential of AFS cells was also evaluated with transplantation after in 
vitro expansion. 
Results: Mouse AFS cell number changes during the course of gestation. At E12.5 
these cells express hematopoietic markers (CD45, CD34, SCA1), mesenchymal 
markers (CD90, CD105) together with Flk1, CD31 and CD44. Gene expression 
analysis showed that mouse AFS cells express at low levels Oct4 and Sox2 and at 
high levels c-Myc and Klf4, whereas they are negative for the expression of 
myogenic genes. 
Mild muscular mutant HSA-Cre, Smn
F7/F7
 mice die at the age of 10 months and 
show evident clinical complications such as kyphosis and muscle shrinkage. After 
transplantation with GFP+ AFS or bone marrow (BM) cells mice survival rate 
increased by 75% and 50% respectively. Animals treated with AFS cells recovered 
more than 75% of force compared to the untreated. One month after 
transplantation, muscles obtained from AFS-treated mice displayed 37% of GFP+ 
fibers, with very low number of regenerating myofibers (<1%) and normal 
dystrophin expression. Fifteen months after transplantation BM-treated mice 
displayed a high number of central nucleated fibers and consistent infiltration of 
interstitial tissue and no GFP+ myofibers, while AFS-treated mice had a 
normalized phenotype, close to the same age WT mice, and 58% of the 
myofibers were GFP+. Similar results were obtained with transplantation of 
mouse AFS cells expanded in culture. 
Discussion: Mouse AFS cells are a heterogeneous population, and their 
phenotype changes during the course of gestation. At E12.5 they express 
mesenchymal, hematopoietic and endothelial markers, but most importantly do 
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not express myogenic factors, indicating that no myogenic progenitor cells are 
present in this stem cell population.  
When injected in a muscular mutant mouse model, AFS cells showed a myogenic 
potential, even after long-term transplantation, suggesting an interesting 
therapeutic potential. They indeed were able to differentiate into satellite cells 
localizing in the muscle stem cell niche and expressing Pax7, α7integrin and 
SM/c-2.6, exclusively markers of satellite cell population. Moreover, AFS cells 
could contribute to the formation of new myofibers even after in vitro 
expansion. 
 
Part of the results described here produced a scientific paper: 
Amniotic fluid stem cells restore the muscle cell niche in a HSA-Cre, Smn(F7/F7) 
mouse model. 
Piccoli M, Franzin C, Bertin E, Urbani L, Blaauw B, Repele A, Taschin E, Cenedese 
A, Zanon GF, André-Schmutz I, Rosato A, Melki J, Cavazzana-Calvo M, Pozzobon 
M, De Coppi P. 
Stem Cells. 2012 Aug;30(8):1675-84. doi: 10.1002/stem.1134.
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iii. Introduction 
 
Regenerative medicine has been receiving much attention in the last years 
because of possible benefits in clinical practice in both surgical and medical 
fields. The considerable development is mainly due to the discovery of cells with 
peculiar characteristics, described as stem cells, that possess both the capability 
of self-renewal and differentiation into organ-specific cell types. Different 
sources of stem cells have been identified in many adult mammalian tissues, 
such as bone marrow, skeletal muscle, skin and adipose tissue, where they 
contribute to the replenishment of cells lost due to normal cellular senescence or 
injury (De Rosa and De Luca, 2012; Friedenstein et al., 1978; Mauro, 1961; Zuk et 
al., 2002). Mesenchymal stem cells, derived from whole bone marrow, have 
been shown to contribute to regenerating skeletal and cardiac muscle, bone, 
cartilage and also adipose tissues. However, their therapeutic potential is limited 
and, although stem cells in adult tissues may be capable of differentiating into 
more cell types than originally thought, they have a limited cellular regeneration 
or turnover (Ferrari et al., 1998; Gussoni et al., 1999; Siegel et al., 2012). 
In contrast, stem cells derived from embryonic sources have the ability not only 
to proliferate and replace themselves indefinitely, but have also the potential to 
form any cell type. Embryonic stem (ES) cells are derived from the inner cell mass 
of pre-implantation embryos, are pluripotent and demonstrate germ-line 
transmission in experimentally produced chimeras. Other important 
characteristics include growth as multicellular colonies, normal and stable 
karyotypes, ability to be continuously passaged and the capability to 
differentiate into cells of all the three embryonic germ layers (Figure 1). Although 
there is great interest in ES cell research, the use of embryos to harvest cells is 
still associated with unresolved ethical concerns. Moreover, ES cells from some 
species can form teratocarcinomas when injected into histocompatible or 
immunologically compromised mice. Finally, immunological reactions are 
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normally associated to their transplantation because of the different genetic 
profile between donor and recipient (Grinnemo et al., 2008). 
 
 
   
Figure 1. Embryonic stem cells. From the zygote to the blastocyst before implantation. ES cells 
are isolated from the inner cell mass and when put in culture growth as multicellular colonies. 
 
 
In order to overcome problem related to both ethical and immunological issues, 
an alternative approach has been recently shown. Both murine and human 
fibroblasts have been reprogrammed directly to pluripotency by ectopic 
expression of four transcription factors (Oct4, Sox2, Klf4 and Myc) to yield 
induced pluripotent stem (iPS) cells (Takahashi and Yamanaka, 2006; Yamanaka, 
2010). They can be derived from adult human fibroblast and it could be possible 
to envisage in the next future that they could be used for autologous application 
without any rejection problem. Human iPS cells resemble ES cells in morphology, 
gene expression and the capacity to form teratomas in immune-deficient mice. 
However, clinical success with human iPS cells is still far to come and must await 
the development of methods that avoid both potentially harmful genetic 
modification and problems related to their teratogenic potential. 
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1. Amniotic fluid stem cells 
For all those reasons many groups are still focusing on different stem cell 
populations for therapeutic applications. Fetal tissue has been used for autograft 
and allograft transplantation because of its proliferative ability and lack of 
immunogenicity. Fetal tissue can be currently obtained from a biopsy or from 
cord blood sampling of the fetus itself during gestation; however, both 
procedures are associated with a defined morbidity. Fetal tissue can also be 
obtained from aborted embryos, but this resource is limited. Amniocentesis is a 
well established technique for the collection of fluid from the human fetus 
during pregnancy (12 weeks to term). Cultured cells from amniotic fluid are 
widely used for the prenatal diagnosis of genetic disorders. The morphologic 
heterogeneity of these cells is well known and different criteria have been used 
for their characterization (In 't Anker et al., 2003). We have described that 
pluripotent stem cells can be isolated from amniotic fluid, defined as amniotic 
fluid stem (AFS) cells by selection for the expression of the membrane stem cell 
factor receptor c-Kit (CD117), a common marker for multipotent stem cell (De 
Coppi et al., 2007a) (Figure 2). These cells have a high renewal capacity and can 
be expanded for over 250 doublings without any detectable loss of chromosomal 
telomere length. We have described their potential to give rise, in vitro, to 
adipocytes-, hepatocytes- and endothelial-like cells, and, in vivo, to differentiate 
towards neurogenic and osteogenic lineages. Furthermore, AFS cells could be 
differentiate towards cardiomyogenic lineages, when co-cultured with neonatal 
cardiomyocytes (Bollini et al., 2010; Chiavegato et al., 2007), or hematopoietic 
lineage when transplanted into immuecompromised Rag1
-/-
 mice (Ditadi et al., 
2009). Moreover, rat AFS cells have been able to improve the repair of the 
damaged smooth muscle in a cryoinjured bladder (De Coppi et al., 2007b) and 
the clinical appearance and intestine function when injected in a rat model of 
necrotizing enterocolitis (Zani et al., 2013). 
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Figure 2. Amniotic fluid stem cells. Multipotent AFS cells are isolated by collecting a 
heterogeneous population of cells through amniocentesis and selecting cells that express c-Kit. 
Under appropriate inducing conditions, the c-Kit+ cells can be differentiated into cell of all three 
primary germ layers. 
 
 
2. Spinal muscular atrophy mouse model
 
In order to test the hypothesis that AFS cells could functionally engraft also in a 
diseased skeletal muscle, we used a mouse model of spinal muscular atrophy 
(SMA), in which the phenotypic disease is full blown in muscle tissue (Nicole et 
al., 2003).  
Spinal muscular atrophy is an autosomal recessive disorder that affects the spinal 
cord neurons, and is clinically characterized by muscle weakness and genetically 
by mutations in the survival motor neuron (SMN) gene. Children with SMA 
experience weakness over a wide range of severity. Type 1 SMA patients are 
never able to sit independently and generally die in infancy. Type 2 SMA can sit 
but often develop severe pulmonary and orthopedic complications, and type 3 
SMA children acquire the ability to walk although this might be lost during the 
course of the disease. In all forms of SMA the most rapid rate of decline is early 
in the course of the disease, with a progressively slower rate of decline over the 
time, and sometimes years are needed to appreciate any further deterioration 
(Crawford, 2004). At the present, no effective therapy is available for SMA, 
besides supportive care. Consequently, the development of novel therapies in 
SMA now has strong academic, government, and industry involvement, in 
addition to the interest of several parental organizations and foundations. 
 
15 
There are normally two copies of SMN gene on each chromosome, the primary 
gene copy called SMN1, and almost an identical copy, SMN2. Loss of SMN1 is 
essential to the pathogenesis of SMA, while the severity of the disease is 
primarily related to the number of copies of SMN2. In contrast to the human, the 
mouse Smn gene is not duplicated, which may explain the fact that the 
conventional knockout of the SMN gene results in embryonic lethality (DiDonato 
et al., 1997; Schrank et al., 1997; Viollet et al., 1997). 
In our mouse model, the murine Smn exon 7 (the most affected exon in human 
SMA) is flanked by two LoxP sequences (Smn
F7
) and deletion is occurring only in 
skeletal myofibers by placing the Cre recombinase under the control of the a-
skeletal actin gene promoter (HSA-Cre). Similarly to other models of muscle 
disease, HSA-Cre, Smn
F7/F7 
mice display a high proportion of myofibers with 
central nuclei, which lead with time to muscle fibers necrosis, heterogeneous 
myofiber diameters, and infiltration of interstitial tissue (Nicole et al., 2003). 
HSA-Cre, Smn
F7/F7
 animals manifest kyphosis, progressive muscle weakness, 
shrinkage, and subsequent respiratory arrest, similarly to the clinical features 
exhibited by the dystrophic mdx/mTR mouse model (Sacco et al., 2010). 
Therefore, the overall survival of HSA-Cre, Smn
F7/F7
 animals is estimated to be of 
10 months. It has been shown that after bone marrow (BM) transplantation, the 
myopathic phenotype attenuates and myofibers number and motor 
performance normalize up to 9 months of age (Salah-Mohellibi et al., 2006). 
However, the engraftment in the diseased muscle tissue is poor: the cells are not 
able to rescue the phenotype and make a substantial, long-term therapeutic 
contribution (Salah-Mohellibi et al., 2006). 
 16 
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iv. Aim 
 
Since the total absence of potential therapies to treat SMA disorder, the 
development of novel therapies in SMA has strong interest. 
The aim of this work was to establish whether AFS cells transplantation would 
produce physiologically and functionally significant skeletal muscle repair in the 
HSA-Cre, Smn
F7/F7
 mouse model, with integration in the muscle niche and 
differentiation into satellite cells. 
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vi. Materials and Methods 
 
1. Mice 
Male C57BL/6 (Ly5.2) GFP+/-mice and female C57BL/6 (Ly5.2) GFP-/- mice were 
used to obtain both Ly5.2 GFP+/- and GFP-/- embryos. HSA-Cre, Smn
F7/F7
 mice 
were used as recipients. All procedures were approved by the University of 
Padua’s Animal Care and Use Committee (CEASA, protocol references 107/07 
and 41056) and, in accordance with Italian law, were communicated to the 
Ministry of Health and local authorities. 
 
2. Amniotic fluid collection and stem cell selection 
Embryo age was defined relative to the morning of vaginal plug discovery (E0.5). 
All dissections were performed under a stereomicroscope (Leica Microsystems). 
Amniotic fluid samples were harvested from pregnant mice at E12.5. 
Amniocentesis has been done following an accurate procedure: first there was 
the removal of maternal uterine wall, to expose the yolk sac. At this point the 
chorion and yolk sac were carefully removed. Amnion rupture resulted in 
amniotic fluid leakage, and amniotic fluid was harvested with a syringe fitted 
with a 28-gauge needle. Mouse amniotic fluid-derived c-Kit+ cells were isolated 
using the Miltenyi Mouse Lineage Cell depletion kit and the CD117 MicroBeads 
kit (all from Miltenyi Biotech).  
 
3. Flow cytometry analysis 
Flow cytometry was performed using a FACSCalibur flow cytometer (BD 
Biosciences) with CellQuest acquisition software (BD Biosciences). The antibodies 
used were CD177 APC (Biolegend) or CD117 PE Cy5 (eBioscience), Sca1 FITC, 
CD90 FITC, CD44 FITC, CD45 PE and CD105 PE (All from BD Biosciences), and the 
7AAD (BD pharmingen) as viability probe. 
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4. Bone marrow collection 
Wild-type (WT) BM cells were isolated under sterile conditions from 6- to 10-
week-old isogenic mice that ubiquitously expressed green fluorescent protein 
(GFP). The femur and tibia were surgically removed and placed in Dulbecco’s 
modified Eagle’s medium (DMEM) culture medium with 10% fetal bovine serum 
(FBS) (Gibco). Marrow was collected and red blood cells were lysed with 0.75% 
NH4Cl in 20 mM Tris, pH 7.2. 
 
5. Fetal liver cells isolation and selection  
Fetal liver samples from GFP+ embryos were harvested between embryonic days 
E11.5 and E13.5, as described for amniotic fluid. After mechanical 
disaggregation, murine fetal liver c-kit+ cells were isolated using the Miltenyi 
Mouse Lineage Cell depletion kit and then CD117 MicroBeads using the same 
protocol validated with AFS cells. 
 
6. AFS cell expansion  
Freshly isolated GFP+ AFS cells were plated onto a feeder layer of mitomycin C-
treated mouse embryonic fibroblasts SNL (applied Stem Cells Inc.) in DMEM 
knockout (Invitrogen) supplemented with 15% heat-inactivated FBS (Invitrogen), 
0.1 mM nonessential aminoacids (Invitrogen), 2 mM L-glutamine (Invitrogen), 50 
U (ug)/ml penicillin/streptomycin (Invitrogen), 0.01 mM 2-mercaptoethanol 
(Sigma), 10 ng/ml BMP4 (R&D Systems), and 20 ng/ml LIF (Sigma). Cells were 
cultivated at 37°C and 5% CO2.  
 
7. Cell injection 
Three-month-old HSA-Cre,Smn
F7/F7
 mice were randomized to receive either no 
treatment, mouse BM cells, or mouse AFS cells. Approximately 25,000 GFP+ cells 
were injected via tail vein in the AFS cells group and  50,000 GFP+ cells were 
injected via tail vein in the BM group. In vitro expanded AFS cells were sorted 
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with an Aria FACS system (Becton Dickinson) and selected for the expression of 
GFP and c-kit prior to injection. After sacrifice at 1 month post-transplantation 
(pt), muscle differentiation and regeneration were investigated by assessing the 
percentage of cells derived from donor GFP+ cells in recipient muscles, 
considering the total number of muscle fibers (both centrally nucleated and with 
peripheral nuclei).  
 
8. Secondary transplants 
Single myofibers were isolated from BM- and AFS-transplanted animals and from 
C57BL/6 GFP+/- mice, as previously described (Rossi et al., 2011). Briefly, 
extensor digitorum longus (EDL) and Soleus muscles were digested for 2 hours at 
37C in 0.2% (wt/vol) type I collagenase (Sigma-Aldrich), reconstituted in DMEM 
(high glucose, with L-glutamine, supplemented with 1% penicillin-streptomycin; 
Invitrogen). Following digestion, muscles were transferred in DMEM (low 
glucose; Invitrogen) on a horse serum (Invitrogen)-coated 10-cm dish (Falcon; BD 
Biosciences) and gently triturated with a wide-bore pipette to release single 
myofibers. Fresh satellite cells (SCs) were stripped off the fibers by repeated 
passage through an 18-gauge needle. Five hundred cells were injected locally 
into tibialis anterior (TA) of naive, 3-month-old HSA-Cre, Smn
F7/F7 
mice. Animals 
were sacrificed at 1 month pt. 
 
9. In vivo imaging 
Prior to imaging, mice were anesthetized (with a mixture of Rompum and Zoletil 
given i.p.), shaved and depilated to completely remove hair, and imaged on the 
eXplore Optix time-domain imager (ART, Montreal, Quebec). Image processing 
and data analysis were performed using explore Optiview 1.04 software (ART). 
 
10. Muscle physiology, histology, and immunofluorescence 
analyses 
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In vivo determination of gastrocnemius strength and contraction kinetics was 
carried out as described previously (Blaauw et al., 2008). Transverse sections (8–
10 µm thick) of isopentane-frozen skeletal muscle (TA) of 3-month-old 
transplanted mice were stained with hematoxylin and eosin and Masson’s 
trichrome. To evaluate the total number of centrally nucleated muscle fibers, 
serial 40 µm sections of the entire TA muscle were prepared. Immunostaining of 
GFP or dystrophin was performed using rabbit anti-GFP (1:200; Invitrogen) or 
anti-dystrophin (1:150; Abcam). Sections were mounted with Vecta-shield and 
4,6-diamidino-2-phenylindole (Vector Laboratories), observed under an Olympus 
BX60 microscope (Olympus), and pictures taken using Viewfinder Lite software. 
 
11. Image processing 
A total of 38 images related to 6 types of muscle fibers were analyzed to 
highlight the different fiber dimension distribution through a quantitative 
evaluation. To this aim, for each image, fibers have been segmented and their 
boundaries analytically obtained by using an automatic procedure and tuned for 
the specific case study. Then, the shape data have been collected from each 
group and the area computation has been performed numerically, and finally 
summarized with mean and variance (due to the high number of samples). 
 
12. Western blot 
Frozen skeletal muscles (TA of affected mice (n=2), TA of AFS- (n=4) and BM- 
(n=4) treated mice 1 month pt and TA of AFS- (n=2), BM- (n=2) 15 months pt) 
were crashed with mortar and pestle in liquid nitrogen and transferred in RIPA 
buffer with protease inhibitor cocktail (Sigma). Anti rabbit GFP (1:700, 
Invitrogen) and anti mouse Actinin (1:5000, Sigma) were used. 
 
13. RNA extraction and Real Time PCR 
Total RNA has been extracted from freshly isolated AFS cells or muscle samples 
using RNeasy Plus Mini kit (QIAGEN GmbH) following the supplier’s instructions. 
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RNA has been then quantified with a ND-1000 spectrophotometer (Thermo 
Scientific) and 1 µg has been retrotranscripted with SuperScript II and related 
products (all from Invitrogen) in a 20 µl reaction. Real-time PCR (qRT-PCR) 
reactions were performed using a LightCycler II (Roche). Reactions have been 
carried out in triplicate using 4 µl of FASTSTART SYBR GREEN MASTER (Roche) 
and 2 µl of primers mix FW plus REV (final concentration, 300/300 nM) in a final 
volume of 20 µl. Serial dilutions of a positive control sample have been used to 
create a standard curve for the relative quantification. The amount of each 
mRNA has been normalized for the content in β2-microglobulin. Primer 
sequences are listed in Table 1.  
 
14. DNA extraction and PCR analyses 
DNA from organ and tissues samples was extracted with a DNeasy Blood & 
Tissue kit (QIAGEN GmbH) and then quantified with a ND-1000 
spectrophotometer (Thermo Scientific). Genomic DNA samples extracted from 
GFP+ AFS cells and from WT organs were, used respectively as positive and 
negative controls for the amplification of the GFP gene. PCR reactions for the 
TERT and GFP genes were carried out as previously described (Ghionzoli et al., 
2009). Primers sequences listed in Table 1. 
  
15. Statistical analyses 
Values were reported as means ± SD or SE. Statistical significance of the 
differences between means were assessed by analysis of variance followed by 
the Student−Newman−Keuls test or by Student's t−test for paired or nonpaired 
data. Statistical significance was set at P< 0.05. 
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Table 1. Primers list. 
Name Forward 5' >3' Reverse 5' >3' 
c-kit TGGTCCGCTGCCCTCTGACA CCTTGATGGCTGCCCGCACT 
Oct4 TGGAGGAAGCCGACAACAATGAGA TGGCGATGTGAGTGATCTGCTGTA 
Nanog CCCTTCCCTCGCCATCACACTG GGAAGGGCGAGGAGAGGCAGC 
Sox2 TCGGGGAAGCGTGTACTTAT CATGCACAACTCGGAGATCA 
Klf4 TGCCCCGACTAACCGTTGGCGT GCTGCACCAGCTCCGCCACT 
c-Myc TGCCCGCGATCAGCTCTCCT CGTGGCTGTCTGCGGGGTTT 
Pax7 AGCAAGCCCAGACAGGTGGCG GGCACCGTGCTTCGGTCGCA 
Myf5 ACAGCAGCTTTGACAGCATC AAGCAATCCAAGCTGGACAC 
Mrf4 GGCTGGATCAGCAAGAGAAG AAGAAAGGCGCTGAAGACTG 
MyoD CGCTCCAACTGCTCTGATG TAGTAGGCGGTGTCGTAGCC 
Myogenin GCAATGCACTGGAGTTCG ACGATGGACGTAAGGGAGTG 
β2microgl. GCTTCAGTCGTCAGCATGG CAGTTCAGTATGTTCGGCTTCC 
GFP TGAACCGCATCGAGCTGAAGGG TCCAGCAGGACCATGTGATCGC 
TERT ACCCACTATCCTTGTGGTGCATGA AGATCGAGCAGCTGCAAGACCATA 
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vi. Results 
 
1. Mouse AFS cell characterization 
Mouse amniotic fluid was collected from offspring of GFP-/- female and GFP+/- 
males, and all the analyses were performed on cells selected for GFP expression 
to avoid any maternal contamination (Figure 3A). A lineage depletion for 
hematopoietic lineage was done on the collected amniotic fluid, to remove all 
the mature cells, and after that a selection for the marker c-Kit was carried out. 
About 1% c-Kit positive cells were detected among all amniotic fluid cells isolated 
at E12.5, and the total number of mouse AFS cells per embryo equivalent was 
around 16.000 cells (Figure 3B).  
As mentioned before, human AFS cells were characterized for their expression of 
pluripotency markers like Oct4 and SSEA4. Mouse AFS cells were indeed studied 
for the expression of the pluripotency markers Oct4, Sox2, Nanog, c-Myc and 
Klf4. Real Time-PCR analysis showed that the expression of these markers was 
very low if compared with that of mouse ES cells, and importantly, mouse AFS 
cells did not express Nanog (Figure 3C). 
 
Figure 3: Presence of mouse AFS cells in the mouse amniotic fluid. (A) Mouse amniotic fluid 
collection. (B) Left panel: percentage of mouse AFS cells at E12.5. Right panel: total number of 
mouse AFS cells per embryo equivalent (EE). Means are represented by bars. (C) Gene expression 
profile of AFS cells collected at E12.5. 
A 
C 
B 
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An immunophenotype analysis was performed to characterize E12.5 mouse AFS 
cells: they express characteristic markers of hematopoietic (CD45, CD34, Sca1) 
and mesenchymal (CD90, CD105) stem cells together with CD44, CD31 and Flk1 
(Figure 4). Considering the c-Kit+ sub-population, CD90 was expressed by 30% of 
cells; CD45, a marker that define the commitment to the hematopoietic lineage, 
was expressed by 32% of cells; CD31 (platelet endothelial cell adhesion molecule 
1, Pecam-1) is a marker expressed by endothelial cells, and its expression in the 
c-Kit+ cells ranged from 12 to 25%. CD34, a hematopoietic stem cells marker, is 
expressed by 20% of cells. Flk1, the receptor for vascular endothelial growth 
factor (VEGFR), changed consistently among all the analyzed sample, indeed it 
was expressed from 5% to 50% of AFS cells isolated at E12.5; Sca1, a 
characteristic marker of hematopoietic stem cells and other adult stem cells, was 
expressed by 20% of the cells. CD105 is another marker of mesenchymal stem 
cells, and it was expressed by 40% of the c-Kit+ cells; CD44 is a cell surface 
glycoprotein involved in cell-cell interactions, and in the amniotic fluid was 
expressed by more than 50% of c-Kit+ cells. 
 
Figure 4: Phenotypic characterization of E12.5 mouse AFS cells. Mouse AFS cells were stained 
with antibodies specific for CD90, CD45, CD31, CD34, Flk1, Sca1, CD105 and CD44. The 
histograms show expression of the markers and the table shows percentage of expression with 
mean and s.d.  
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Since the heterogeneity of AFS cells, we performed a myogenic expression 
profile to exclude the presence of muscle precursor cells in the c-Kit positive 
selected population. As shown in Figure 5, we didn’t find expression of either 
early or late myogenic specific genes. 
 
Figure 5: Expression of myogenic genes. Three sample of mouse AFS cells and BM cells were 
freshly isolated and analyzed for the expression of specific myogenic genes to exclude the 
presence of myogenic precursor cells among all the selected cells. Muscle precursor cells  (MPC) 
were used as positive control. 
 
 
2. AFS cell transplantation in mild muscular atrophy mouse 
model 
At the age of 3 months, mutant mice (HSA-Cre, Smn
F7/F7
) were randomized to 
receive via tail vein GFP+ AFS cells (25,000 cells, n=40), GFP+ BM cells (50,000 
cells, n=20), or no treatment (untreated, n=20). AFS cells were derived and 
characterized as previously described. As expected, all untreated animals died by 
the age of 10 months, whereas the BM- and AFS-treated groups had at that time 
survival rates of 50% and 75% (p < 0.001), respectively (Figure 6A). The treated 
mice dramatically differed from the untreated animals: gastrocnemius 
contraction kinetics was measured blinded 1 month pt and this analysis 
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confirmed that both BM- and AFS-treated mice achieved strength levels 
comparable to the ones obtained with WT mice (Figure 6B). Remarkably, the 
AFS-treated animals, which survived until 15 months pt (i.e., 18 months of age), 
maintained the strength acquired at 1 month pt (Figure 6B). Consistently with 
survival and muscle strength, AFS-treated mice were similar to WT mice in terms 
of diaphragm thickness, weight, movement, and skeletal anatomy as confirmed 
at MicroCT scan analysis (Figure 6C-F). On the contrary, HSA-Cre,Smn
F7/F7
, which 
did not receive any treatment, showed typical thinner diseased diaphragmatic 
muscles at 4 months of age (Figure 6C) and pronounced kyphosis with impaired 
movements by the age of 8 months (Figure 6D-F).  
 
Figure 6: Transplanted animals improve in survival and clinical parameter. (A) Survival curve: 
AFS-treated mice increased life expectancy both when compared to BM-treated and untreated 
animals. Untreated=10 animals, BM=8 animals, AFS=8 animals (***p<0.001). (B) Left panel: 
muscle strength analyzed at different frequencies; right panel: mean value of muscle strength 
analyzed at 150 Hz of frequency. Normalized force frequency on muscle mass displays that both 
BM- (n=8) and AFS-treated (n=8) mice had 75% more muscle strength than untreated (n=6) 
animals one month after transplantation (***p<0.001). AFS-treated animals analyzed at 18 
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months of age (Green dotted line; n=4). (C) Diaphragm thickness one month after transplantation 
(n=3/group), in AFS-treated animals did not differed from age-matched WT animals while they 
are both distinct from untreated animals (scale bar =100 µm; *p<0.05). (D) Bodyweight of 
untreated (n=4), AFS-treated (n=4) and WT (n=8) mice at 8 months (***p<0.001). (E) The 
kyphosis, which is present in the untreated mice from 3 months of age, disappeared in AFS-
treated mice. (F) MicroCT scan of skeletal anatomy of untreated and AFS-treated mice confirmed 
the different curvature of the spine. 
 
When fiber diameter was measured, at first both AFS- and BM-treated muscles 
demonstrated a normalization of dimensions close to WT muscle; notably in the 
long-term experiments this normalization was maintained only by the AFS-
treated muscles, while those treated with BM had very large hypertrophic fibers 
(Figure 7). 
 
 
Figure 7: Stem cells-treated fibers diameter. (A) Distribution of fiber areas in WT (black), AFS-
treated (green), BM-treated (red) and untreated (blu) muscles, 1 month and 15 months (dotted 
lines) after transplantation. (B) Example of dystrophin expression in all the analyzed samples. 
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3. Restoration of muscle phenotype after AFS cell 
transplantation  
Following morphological muscle analyses performed 1 month pt (i.e., 4 months 
of age; Figure 8A), in both BM- and AFS-treated mice, the histological aspect of 
the muscle tissue resulted indistinguishable from WT, with few central nucleated 
fibers (<1%, comparable to WT mice; Figure 8B, 8F, 8G). In contrast, untreated 
animals presented a very large number of central nucleated fibers (mean value: 
63.70% ± 0.41%, p < 0.001 vs WT; Figure 8B, 8F, 8G). Masson’s trichrome staining 
showed that untreated animals presented large connective tissue areas between 
fibers, which were absent in both WT and cell-treated mice. 
Immunofluorescence analyses clearly indicated that the morphological 
appearance of muscle in BM- and AFS-treated animals was correlated with a 
relevant proportion of GFP+ fibers (31.57% ± 7.04% and 37.86% ± 9.48%, 
respectively; Figure 8G).  
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Figure 8: Restoration of muscle phenotype in mutant mice. (A) Three-month-old HSA-Cre, 
Smn
F7/F7 
mice were transplanted alternatively with BM or AFS cells and sacrificed 1 month after 
treatment for analyses. (B) One month after transplantation, H&E staining reveal a normal 
appearance of the TA muscle structure after receiving either BM or AFS cells. On the contrary TA 
muscle of untreated animals present fibers disarrangement (dystrophin staining) with interstitial 
tissue deposition identified at Masson’s trichrome. Scale bar=100 µm. (C) Regeneration index 
indicates that AFS cells are more likely to participate in muscle regeneration than BM 
cells;***p<0.001. (D) qRT-PCR for Pax7 expression revealed that mutant muscles receiving AFS 
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cells (n=3) expressed higher levels of Pax7 than untreated (n=3) and BM (n=3) animals; *p<0,05. 
(E) Fifteen months after transplantation, histological and immunofluorescence analyses revealed 
a more sustained, long-term engraftment of AFS cells, relative to BM cells. Scale bar =100 µm. (F-
G) Graphs of raw numbers (each letter on the x axis is an individual muscle evaluated in 3 
representative high power fields) and percentages of centrally nucleated and GFP+ fibers on total 
number of fibers/area. 
 
It is worth of notice that in this particular muscular model, the beneficial effect of 
AFS cells transplantation is detectable very soon after injection. In fact, only 12 
hours after injection the number of centrally nucleated fiber greatly diminished 
(7.90% ± 2.31%) to look similar to WT muscle only after 7 days (0.53% ± 0.09%). 
Importantly, as shown before, this in vivo effect did not relate to the presence of 
myogenic precursors in the transplanted populations, which was excluded by 
demonstrating that the myogenic genes Pax7, MyoD, Myf5, Mrf4, and Myogenin 
were neither expressed in freshly isolated BM nor in AFS cells (Figure 5). Last, 
massive changes in the muscle tissue were also confirmed by the observed 
distribution of dystrophin expression, which was similar in transplanted mice 
compared to WT but was altered  in the untreated animals (Figure 8B). It was not 
possible to consider the restoring of the Smn protein as amelioration in the 
transplanted animals since Smn is expressed also in the HSA-Cre, Smn
F7/F7
 mice 
(Nicole et al., 2003). Despite the similarity between BM- and AFS-treated animals 
in terms of physiology and number of central nucleated and GFP+ myofibers, the 
engraftment index, defined as the number of donor-engrafted myofibers 
generated per 10
5
 transplanted cells (Carraro et al., 2008), differed significantly 
between BM- (1,263.00 ± 282.76) and AFS-treated mice (3,029.16 ± 758.71; p < 
0.001), respectively (Figure 8C). Additionally, qRT-PCR revealed that 1 month 
after treatment, in the TA muscles of AFS-treated mice, there was higher 
expression of Pax7 than in untreated or BM-treated mice (p < 0.05; Figure 8D). 
Further evidence of the differences between the two groups was confirmed by 
analysis of surviving animals 15 months pt (Figure 8A). Morphological analysis of 
samples from BM-treated mice displayed a high number of central nucleated 
fibers (39.90% ± 17.68%) and consistent infiltration of interstitial tissue between 
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the myofibers — a situation that differed greatly from the one observed in AFS-
treated mice, where tissue appeared healthy and compact (Figure 8E-8G). 
Moreover, at this stage (15 months pt), no GFP+ fibers were found in BM-treated 
animals, whereas 58.00% ± 2.43% of myofibers were GFP+ in AFS-treated mice 
(Figure 8E-8G). This finding highlights the sustained effect of AFS cells 
transplantation. PCR analyses of genomic GFP performed 1 and 15 months pt 
proved that the AFS cells were able to engraft systemically throughout various 
skeletal muscles (Figure 9A) and this was also confirmed after Western blot 
performed in muscle samples (Figure 9B). The ability of AFS cells to engraft 
various skeletal muscle tissues was also validated by the fact that both the 
number of central nucleated and GFP+ fibers were comparable among 
gastrocnemius, EDL, and diaphragm at 1 month pt, with GFP+ fibers variation 
from 17.28% ± 3.66% for diaphragm to 38.52% ± 6.87% for EDL (Figure 9C). 
Moreover, this could also be explained by the migratory potential of AFS cells 
that is consistent, besides the skeletal muscle territory, with the multiple organ 
engraftment similar to the one observed after systemic injection of human AFS 
cells (Carraro et al., 2008) (Figure 9D). 
 
 
Figure 9: AFS cells distribution after tail vein injection. (A) PCR analyses of gastrocnemius, TA 
and diaphragm muscles isolated from AFS-treated mice one and fifteen months after 
D 
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transplantation. First lane: amplification of the GFP gene (307 bp) in AFS-treated HSA-Cre, 
Smn
F7/F7
 mice. Second lane: amplification of genomic TERT (132 bp) to confirm the quality of the 
extracted DNA. (B) Western blot analysis for GFP detection of TA muscles from untreated, BM- 
and AFS-treated mice obtained 1 month pt and from BM- and AFS-treated animals sacrificed 15 
months pt. Actinin was used to confirm the quality of protein extraction. (C) Immunofuorescence 
analysis of gastrocnemius, EDL and diaphragm obtained from untreated and AFS-treated mice 
one month after transplantation and relative percentage of GFP+ and central nucleated 
myofibers. Scale bar =100 µm. (D) Immunofluorescence analyses with anti-GFP antibody in the 
brain, liver, spleen and lung of AFS-treated mice showed minimal systemic engraftment. The 
same and other organs were analyzed by PCR, first lane: amplification of the GFP gene; second 
lane: amplification of genomic TERT to confirm the quality of the extracted DNA. The positive 
control (Pos Ctrl) for GFP amplification was the genomic DNA extracted from GFP+ AFS cells; the 
negative (Neg Ctrl) was a TA of WT mouse; NT Ctrl=no template control; Muscle: lysate of 
gastrocnemius, TA and EDL treated muscles. 
 
 
4. AFS cells engraft in the muscle stem cell niche and 
express satellite cell markers 
Since AFS cells were able to sustain long-term muscle regeneration, we assumed 
that they were able to integrate into the muscle stem cell niche. In AFS-treated 
muscles, GFP+ cells were found in sublaminal position, and this observation was 
evident also when fibers were isolated in culture (Figure 10A, 10B). Moreover, 
some of these cells co-stained for Pax7 and alpha7integrin (α7int) both when 
adherent to the fiber and after stripping (Figure 10C-E). 
 
Figure 10: AFS cells differentiate in muscle stem cells. (A) Immunofluorescence of TA muscle 
from AFS-treated mouse; GFP+ cells are localized in the sub-laminal zone (GFP in green, Laminin 
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in red). (B) Detection of GFP+ cells in isolated fiber. (C) Immunofluorescence of Pax7 (red) and 
GFP (green) in fiber isolated from TA muscle of AFS-treated animal. (D-E) Cytospin of SC isolated 
from TA muscle of AFS-treated mouse. Co-expression of Pax7 and alpha7integrin with GFP 
demonstrated the differentiation of AFS cells in muscle stem cells. Scale bars =100 µm. 
 
An evaluation of muscle satellite cell population  was performed 1 month post-
transplantation (4 month-old mice) using Pax7 immunostaining and validated by 
cytofluorimetric analysis of SM/C-2.6 (Ikemoto et al., 2007). As appears in the 
figure 11, the two data confirmed the PCR analysis reported before (Figure 8D) 
and consistently showed that the number of myogenic progenitors in the AFS-
treated muscle is higher (8,05% in AFS-treated vs 0.90% in untreated; Figure 11) 
than in both WT and untreated muscles. The latter is possibly due the exhaustion 
of satellite cells in the HSA-Cre, Smn
F7/F7 
mice which at 4 months show already 
macroscopical signs of the disease and inevitably die by the age of 9-10 months. 
This data differ from what has been observed in mdx mice (Reimann et al., 2000) 
and Duchenne muscular dystrophy patients (Kottlors and Kirschner, 2010), were 
the number of satellite cells does not decrease even at advanced state of 
diseases.  
 
Figure 11: AFS cells trans-differentiate into satellite cells. In AFS-treated muscles were found 
Pax7+ cells located under the fiber basal lamina and, after digestion of whole muscle, we found 
GFP+ SM/C-2.6+ cells, indicating that injected cells were able to differentiate in muscle stem 
cells. 
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To confirm functional integration of AFS cells in the muscle stem cell niche, both 
cardiotoxin injury and secondary transplant experiments were performed. In a 
first set of experiments, cardiotoxin was injected into the TA of BM- and AFS-
treated mice 1 month after systemic cell transplantation (Figure 12A). Only AFS-
treated mice showed newly regenerating GFP+ muscle fibers (51.75% ± 1.35%; 
Figure 12B, 12D) when analyzed 45 days pt, whereas no GFP+ fibers were 
observed in animals previously transplanted with BM cells (Figure 12B, 12D). 
Moreover, almost all fibers in AFS-transplanted mice were perinucleated 15 days 
after damage with cardiotoxin. On the contrary, after injury of BM-treated mice, 
38.07% ± 2.54% of the regenerating fibers was centrally nucleated (Figure 12B, 
12C) confirming that only AFS cells were capable of restoring physiological 
muscle conditions. 
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Figure 12: AFS cells fill the muscle stem cell niche. (A) TA muscles of BM- and AFS-treated mice 
were injured with cardiotoxin (Ctx) 30 days pt and animals were sacrificed 45 days pt. For 
secondary transplant experiments, primary transplanted mice were sacrificed 30 days pt, satellite 
cells were isolated from EDL and Soleus muscles and injected into secondary HSA-Cre, Smn
F7/F7
 
hosts, which were sacrificed and analyzed 30 days later. (B-D) Ctx injury: Fifteen days after Ctx 
injury, only AFS-treated mice displayed GFP+ fibers. Graphs of raw number and percentages of 
central nucleated (untreated 63.70%±3.24; BM-treated 38.07%±6.73; AFS-treated <0.1%; 
***p<0.001) and GFP+ fibers (untreated 0%; BM-treated 0%; AFS-treated 51.75%±1.35; 
***p<0.001) in untreated, BM- and AFS-treated mice demonstrated that only AFS cells efficiently 
regenerate skeletal muscle fibers. (E-F) Secondary transplants: Thirty days pt, GFP+ fibers were 
observed in all 6 mice injected with SC derived from AFS-treated mice (31.47%±2.63), but only in 
one out of 6 mice transplanted with SC derived from BM-treated mice (4.80%±3.86; **p<0.01). 
Scale bar = 100 µm. A,B,C letters on the x axis in graphs c and e represent an individual muscle 
evaluated in 3 representative high power fields. (G) PCR analysis confirmed that TA muscle 
treated with SC isolated from primary AFS-treated mice expressed GFP. Amplification of the GFP 
gene (307 bp) and TERT (132 bp) in TA muscles of untreated, secondary BM-treated (BM), 
secondary AFS-treated (AFS) and GFP+ SC-treated (SC) HSA-Cre, Smn
F7/F7
 mice. (Positive control: 
genomic DNA from GFP+ AFS cells. NTC=no template control).   
 
To further establish whether AFS cells were truly engrafted into the muscle niche 
and replaced resident muscle stem cells, secondary transplants were performed 
(Figure 12A). Single myofibers were isolated from BM- (n=6) and AFS- (n=6) 
transplanted animals and from WT C57BL/6 GFP+ mice (n=3), as previously 
described (Montarras et al., 2005; Rossi et al., 2011). Five hundred freshly 
isolated SCs, disengaged from single myofibers, were injected locally into TA 
muscles of naive, 3-month-old HSA-Cre, Smn
F7/F7 
mice. One month after 
secondary transplantation, all the mice in the AFS cell group (n=6) had GFP+ 
fibers (mean: 31.47% ± 2.63%; Figure 12E, 12F) and did not differ significantly 
from hosts having received WT GFP+ SCs (mean 32.21% ± 3.39%; Figure 12E, 
12F). In contrast, only one out of six of the recipients of muscle cells derived 
from BM-treated mice had a few GFP+ fibers (4.80% ± 3.86%). Furthermore, this 
pattern was confirmed by PCR analysis of GFP genomic DNA in TA muscles of the 
secondary transplanted animals (Figure 12G). 
To exclude that AFS cells potential to regenerate skeletal muscle even after 
cardiotoxin injury was simply related to their fetal origin, c-Kit+ fetal liver (FL) 
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cells were used as further control. Interestingly, c-Kit+ FL cells did not differ from 
BM cells and GFP+ fibers were not found after cardiotoxin injury confirming the 
unique muscle regeneration potential of AFS cells (Figure 13). 
 
Figure 13: Fetal liver and muscle. (A) FL-treated mice were sacrificed 30 days after 
transplantation or 15 days after cardiotoxin injury (45 pt). (B) One month after systemic injection 
of c-Kit+ GFP+ Fetal liver cells (FL), TA of mutant mice displayed a relative high number of GFP+ 
fibers, but 15 days after ctx injury (45 days pt), no GFP+ signal was founded. Scale bar =100 µm. 
(C) Percentage of GFP+ fibers and central nucleated myofibers of TA before and after ctx injury. 
(D) PCR analysis of muscles from FL-treated mice 1 month after cell injection. 
 
5. In vitro expanded AFS cells preserve myogenic potential 
Given the poor recovery of freshly isolated AFS cells and the strong therapeutic 
interest, we explored the myogenic potential of ex vivo-expanded AFS cells 
(Figure 14A). After 2 weeks of culture on fibroblast feeder layer (Figure 14B), AFS 
cells were sorted for the dual expression of GFP and c-Kit (89.50% ± 6.27%) and 
then transplanted in 3-month-old HSA-Cre, Smn
F7/F7
 mice. Similarly to what had 
been observed with freshly isolated AFS cells, the muscles of treated mice 
displayed, 1 month after treatment, a normal phenotype with well-organized 
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dystrophin expression, less than 1% centrally nucleated fibers, and 21.01% ± 
3.57% GFP+ fibers (Figure 14C, 14D). Multiple skeletal muscle engraftments in 
the transplanted animals were also confirmed by PCR analyses of genomic GFP 
(Figure 14E). 
 
Figure 14: Transplantation of expanded AFS cells generates skeletal muscle tissue. (A) After 15 
days of culture, AFS cells GFP+/c-Kit+ were sorted and injected in HSA-Cre, Smn
F7/F7
 mice. (B) 
GFP+ AFS cells were passaged twice on a mouse embryonic fibroblast feeder layer. Magnification 
10X and 20X for the inlet. (C) Immunofluorescence with anti-GFP and anti-dystrophin antibodies: 
1 month after transplantation, the muscles of treated HSA-Cre, Smn
F7/F7
 mice displayed a 
considerable number of GFP+ fibers and a normal levels of dystrophin expression. Scale bar = 100 
µm. (D) Percentage of GFP+ and central nucleated myofibers in cultured AFS-treated animals. (E) 
PCR analyses of gastrocnemius, TA and diaphragm muscles isolated from mice transplanted with 
cultured AFS cells. First lane: amplification of the GFP gene (307 bp). Second lane: amplification 
of genomic TERT (132 bp) to confirm the quality of the extracted DNA. For each PCR, the positive 
control (Pos Ctrl) for GFP amplification was the genomic DNA extracted from GFP+ AFS cells; 
NTC=no template control. 
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vii. Discussion 
 
AFS cells represent a small percentage of total amniotic fluid cells (around 1%) 
that can be harvested by amniocentesis and enriched by immunoselection using 
anti-CD117 (c-Kit) antibody. Human AFS cells have a high renewal capacity and 
can be expanded for over 250 doublings without any detectable loss of 
chromosomal telomere length. We described their potential to give rise, in vitro, 
to a wide range of cell types representing the three primary embryonic lineages 
of mesoderm, ectoderm and endoderm, and, in vivo, to differentiate towards 
neurogenic and osteogenic lineages (De Coppi et al., 2007a). Since the 
development, especially regarding embryonic annexes, is different among 
mammals, in this work we deeply explored the stemness characteristics of 
mouse AFS cells and their therapeutic potential in a model of muscle disease. 
Our results strongly suggest that AFS cells, but not BM cells, integrate in the 
muscle stem cell compartment and have long-term potential for muscle 
regeneration in HSA-Cre, Smn
F7/F7
 mutant mice. This mouse model, which has 
been extensively characterized, closely replicates the clinical features of human 
muscular dystrophies. When injected systemically into HSA-Cre,Smn
F7/F7
 mutant 
mice, BM cells were not able to rescue the phenotype and have shown a limited 
therapeutic efficiency failing to make a substantial, long-term therapeutic 
contribution (Salah-Mohellibi et al., 2006). Unselected and selected BM cell 
populations have been widely tested in various mouse models of muscle 
diseases, with an initial enthusiasm prompted by cells’ ability to fuse with the 
host muscle tissue (Ferrari et al., 1998; Gussoni et al., 1999) and subsequently 
activate resident SCs (Salah-Mohellibi et al., 2006). However, it is still not clear 
whether BM cells are able to integrate in the muscle stem cell niche and are 
capable of regenerating new fibers after damage (Sherwood et al., 2004; Xynos 
et al., 2010). Mesenchymal stem cells from BM and other sources are able to 
restore dystrophin expression in the mdx mouse, but the impact on muscle 
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repair is dependent on forced expression of MyoD (Choi et al., 1990; De Bari et 
al., 2003; Goudenege et al., 2009). BM stem cells may indeed be therapeutic by 
producing molecules that regulate muscle regeneration or reduce inflammation, 
while they are able to establish immune tolerance in a dystrophic animal model 
and allow stable engraftment of donor muscle-derived cells (Parker et al., 2008). 
More encouraging results have been obtained using stem cells isolated directly 
from muscle tissue. The intra-arterial delivery of niche-derived mesangioblasts 
results in morphological and functional correction of the dystrophic phenotype in 
adult immunocompetent αsarcoglycan null mice (Sampaolesi et al., 2003), in 
SCID/BlAJ mice, a novel model of dysferlinopathy (Diaz-Manera et al., 2011), and 
golden retriever muscular dystrophy dogs (Sampaolesi et al., 2006). 
Alternatively, functional myogenic cells can be also derived from ES cells (Sakurai 
et al., 2008). Intramuscular and systemic transplantation of Pax3+ PDGF-αR+ and 
Flk1+ ES-derived cells into dystrophic mice results in extensive engraftment of 
adult myofibers, with enhanced contractile function and no teratoma formation 
(Darabi et al., 2008). In order to overcome the immunological problem related to 
ES cell transplantation, patient-specific induced pluripotent stem (iPS) cells could 
also be generated (Takahashi and Yamanaka, 2006). Similarly to ES cells, iPS cells 
can both generate in vitro skeletal muscle stem cells, and, after enrichment using 
the anti-SC antibody SM/C-2.6, functionally engraft into skeletal muscle when 
transplanted into mdx mice (Darabi et al., 2011; Mizuno et al., 2010). While ES- 
and iPS-derived myogenic cells may become useful for therapy in the future, a 
readily available source of cells with myogenic potential would be relevant as 
therapeutic alternative to muscle-derived stem cells. Our group has previously 
demonstrated that (a) broadly multipotent stem cells can be derived from 
amniotic fluid (De Coppi et al., 2007a) and (b) freshly isolated murine AFS cells 
show hematopoietic potential when injected in Rag1-/- mice (Ditadi et al., 2009). 
AFS cells have been tested in various disease models and have been shown to 
contribute to organ regeneration (Carraro et al., 2008; Hauser et al., 2010; Rota 
et al., 2011). Similarly to BM cells and mesangioblasts (Sampaolesi et al., 2006), 
AFS cells can cross the endothelial barrier and are therefore suitable for systemic 
 
43 
injection (Carraro et al., 2008; Ghionzoli et al., 2009). However, their myogenic 
potential remains to be fully elucidated. While AFS cells have shown to be able to 
fuse into myotubes (De Coppi et al., 2007a), Gekas et al. failed to show functional 
engraftment of human AFS cells after expansion when injected in 
immunocompromised animals (Gekas et al., 2010). Differently, we show that 
murine AFS cells are able to restore muscle function in a model of disease and to 
maintain a long-lasting therapeutic efficiency possibly because of their unique 
ability of switching toward muscle stem cells. The beneficial effects are tightly 
correlated with the normalization of pathological skeletal muscle regeneration 
and the remarkable attenuation of mutant phenotype (treated animals showed 
neither kyphosis nor abdominal shrink) resulting in the long-term survival 
observed here. We first hypothesized that muscle progenitors were present 
among the AFS cells, but, immediately after c-Kit selection, the AFS cells’ gene 
expression profile was not suggestive of any myogenic commitment within the 
population. 
It is noteworthy that after intravenous cell injection (and despite differences in 
the number of injected cells), BM- and AFS-treated animals possessed similar 
numbers of perinucleated fibers, highlighting the positive effect of cell 
treatment. However, the functional engraftment of the two cell types in the 
affected muscles differs drastically and in order to explain the long-lasting effect 
of AFS cell transplantation, we hypothesized that the fetal cells (in contrast to 
BM cells) were able to migrate into the muscle stem cell niche. This behavior is a 
feature not only of SCs (Collins et al., 2005) but also of other stem cells of muscle 
origins (Cerletti et al., 2008) or perycites, as previously demonstrated (Dellavalle 
et al., 2011). Therefore, the finding of GFP+ cells in sub-laminal position warrant 
our theory. Despite the presence of stem cell progenitors in the BM, our selected 
population of fetal stem cells appears to be more efficient. In fact, 50% of the 
BM-treated mice survived for 18 months, in contrast with 75% of the AFS-treated 
mice. Moreover, only AFS-injected muscles still had a high proportion 
(approximately 60%) of GFP+ fibers more than a year after transplantation. The 
high number of central nucleated fibers observed in BM-treated animals after 
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cardiotoxin injection proved that BM cells failed to functionally integrate into the 
muscle stem cell niche (Sherwood et al., 2004; Xynos et al., 2010), whereas GFP+ 
fibers in AFS-treated muscle resulted not only from cell fusion, but also from de 
novo fiber generation from newly born muscle stem cells. Moreover, the higher 
AFS cell muscle engraftment indicated that a strong ablative preconditioning 
injury enhances the therapeutic effect—possibly because of the selective 
advantage of functionally normal cells in AFS-treated mice. Integration of AFS 
cells in the stem cell niche is also confirmed by secondary transplants in HSA-Cre, 
Smn
F7/F7
 mice of SCs isolated from BM- and AFS-treated animals. Only the latter 
group consistently showed the ability of AFS-derived SCs to form new fibers, 
similarly to what observed in mice injected with SCs derived from C57BL/6 GFP+ 
mice. While SCs have been isolated according to a well-established protocol 
(Collins et al., 2005), we are limited by not using a SCs lineage tracing mouse for 
isolating AFS-derived SCs (Darabi et al., 2008). 
In order to progress toward AFS cells application for therapy, it was also 
important to establish if their myogenic potential could be preserved after 
expansion, as it has been recently demonstrated for alkaline phosphatase 
positive pericytes (Dellavalle et al., 2011; Sampaolesi et al., 2006). Accordingly, in 
vitro expanded AFS cells demonstrated the maintenance of regenerative 
properties after intravenous injection in HSA-Cre, Smn
F7/F7
 mutant mice . Twenty 
percent of the fibers was of donor origin, a remarkable result, given that (a) 
some adult stem and progenitor cells have proved difficult to expand in culture 
and (b) skeletal muscle SCs multiply rapidly in culture but show diminished 
regenerative capacity when transplanted in vivo (Montarras et al., 2005). 
Nevertheless, 20% was lower than the value achieved in animals having received 
freshly isolated AFS cells. Further work is required to assess the relationship 
between myogenic potential and expansion conditions. Moreover, while it is 
clear that AFS cells are capable of restoring normal muscle function in HSA-Cre, 
Smn
F7/F7
 mutant mice primarily by engraftment and differentiation, future work 
will need to address whether bystender effect also has a role in this animal 
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model of disease since it is possible that AFS cells could also activate resident 
Pax7+ SCs (similarly to what has been described for BM cells) (Yoon et al., 2009). 
In conclusion, AFS cells may constitute a promising therapeutic option for muscle 
regeneration, since (a) systemic injection of low cell numbers clearly replenishes 
the muscle stem cell niche and (b) cultured AFS cells also seem to possess a high 
regeneration capacity. These results are relevant for the development of 
efficient treatment of muscle disease where an alternative to SCs is needed 
because of their limitation to be expanded and to migrate through the 
endothelial barrier. In depth studies must be now performed with human AFS 
cells to verify if this new source of stem cells can open unexpected and highly 
required therapeutic approaches for devastating disease like those affecting the 
skeletal muscle tissue. 
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